Joint United Nations Programme on HIV/AIDS.2008 Report on the Global AIDS Epidemic. Geneva, Switzerland: Joint United Nations Programme on HIV/ AIDS, July 2008.
2.
Puvimanasinghe JPA , Ndwapi N., Gaolathe T., et al. Six Years of HAART in the Public Sector of Botswana. XVII International AIDS Conference . August 13-18, 2008. Mexico City, Mexico. Abstract MOAB0204.
3.
Fairall LR, Bachmann MO, Louwagie GMC, et al. Effectiveness of antiretroviral treatment in a South African program: A cohort study. Arch Intern Med. 2008;168: 86-93.
4.
Boulle A., Van Cutsem G., Cohen K., et al. Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy. JAMA. 2008;300:530-539.
5.
Bisson GP, Gross R., Bellamy S., et al. Pharmacy refill adherence compared with CD4 count changes for monitoring HIV-infected adults on antiretroviral therapy. PLoS Med.5:e109.
6.
Office of the Global AIDS Coordinator.PEPFAR - A Commitment Renewed. Washington, DC: Office of the Global AIDS Coordinator; August 2008. Available at: http://www.pepfar.gov/documents/organization/107750.pdf . Accessed November 7, 2008.
7.
American Foundation for AIDS Research.MSM, HIV, and the Road to Universal Access - How Far Have We Come?New York City, NY: American Foundation for AIDS Research ; 2008.
8.
Lundgren J., Neuhaus J., Babiker A., et al. Use of Nucleoside Reverse Transcriptase Inhibitors and Risk of Myocardial Infarction in HIV-Infected Patients Enrolled in the SMART Study . XVII International AIDS Conference; August 13-18, 2008; Mexico City, Mexico. Abstract THAB0305.
9.
Sabin C., Worm S., R Weber R., et al., and the D:A:D Study Group. Do thymidine analogues, abacavir, didanosine and lamivudine contribute to the risk of myocardial infarction? The D:A:D Study. 15th Conference on Retroviruses and Opportunistic Infections; February 3-6, 2008; Boston, Massachusetts, USA. Abstract 957c.
10.
El-Sadr W. and the SMART Study Group.Re-Initiation of ART in the CD4-Guided ART Interruption Group in the SMART Study Lowers Risk of Opportunistic Disease or Death. 15th Conference on Retroviruses and Opportunistic Infections; February 3-6, 2008; Boston, Massachusetts. Abstract 36.
11.
Mascolini M. , Zuniga JMPerceptions of health, HIV disease, and HIV treatment by patients in six regions: analysis of the 2555-person AIDS Treatment for Life International Survey. J Int Assoc Physicians AIDS Care (Chic Ill). 2008;7:160-177.
12.
Wilson KJ, Doxanakis A., Fairley CKPredictors for non-adherence to antiretroviral therapy. Sex Health. 2004;1: 251-257.
13.
World Health Organization/Joint United Nations Programme on HIV/AIDS.Task Shifting: Global Recommendations and Guidelines . Geneva, Switzerland: World Health Organization/Joint United Nations Programme on HIV/AIDS; 2008.
14.
Sherer RD, Dalebout S., Matos D., Prada N., Dalebout S.Serving Orphans and Vulnerable Children in Mozambique and Namibia: Partnerships to Strengthen Micro Credit and Health Education. American Public Health Association 136th Annual Meeting; October 25-29, 2008; San Diego, California, USA. Abstract 178881.
15.
Philbrick WCMicrofinance Programs and Impact on OVC in HIV Contexts. XVII International AIDS Conference ; August 13-18, 2008; Mexico City, Mexico. Abstract MOPE0773.
16.
US Food and Drug Administration.FDA Approves New HIV Drug. Press release issued October 16, 2007. Rockville, MD: US Food and Drug Administration. Available at: http://www.fda.gov/bbs/topics/NEWS/2007/NEW01726.html. Accessed November 7, 2008.
17.
US Food and Drug Administration.FDA Approves Novel Antiretroviral Drug. Press release issued August 6, 2007. Rockville, MD: US Food and Drug Administration. Available at: http://www.fda.gov/bbs/topics/news/2007/new01677.html. Accessed November 7, 2008.
18.
US Food and Drug Administration.FDA Approves New HIV Drug After Priority Review. Press release issued January 18, 2008. Rockville, Maryland, USA; US Food and Drug Administration. Available at: http://www.fda.gov/bbs/topics/NEWS/2008/NEW01783.html. Accessed November 7, 2008.
19.
Merck & Co.Vaccination and Enrollment Are Discontinued in Phase II Trials of Merck's Investigational HIV Vaccine Candidate. Press release issued September 21, 2007. Whitehouse Station, NJ: Merck & Co. Available at: http://www.merck.com/newsroom/press_releases/research_and_development/2007_0921.html . Accessed November 7, 2008.
20.
US National Institute of Allergy and Infectious Diseases.NIAID Will Not Move Forward With The Pave 100 HIV Vaccine Trial. Press release issued July 17, 2008. Bethesda, MD: US National Institute of Allergy and Infectious Diseases. Available at: http://www.nih.gov/news/health/jul2008/niaid-17.htm . Accessed November 7, 2008.
21.
Population Council.Trial Shows Anti-HIV Microbicide Is Safe, But Does Not Prove It Effective. Press release issued February 18, 2008. New York City, NY; Population Council. Available at: http://www.popcouncil.org/mediacenter/newsreleases/Carraguard_Findings.html . Accessed November 7, 2008.
22.
Microbicides Development Programme.Microbicides Development Programme (MDP) Update: MDP301 Phase III Trial Continues But One Arm Closes. Statement released February 14, 2008. London, UK; Microbicides Development Programme. Available at: http://www.mdp.mrc.ac.uk/downloads/MDP_statement_14Feb08_v1[1].2_FINAL.pdf. Accessed November 7, 2008.
23.
Bailey RC, Moses S., Parker CB, et al. The protective effect of male circumcision is sustained for at least 42 months: results from the Kisumu, Kenya Trial. XVII International AIDS Conference; August 13-18, 2008; Mexico City, Mexico. Abstract TUAC0305.
24.
Knapp C.New hope for health in South Africa. Lancet. 2008;372:1207-1208.
